Diversified Trust Co Purchases 309 Shares of AstraZeneca PLC (NASDAQ:AZN)

Diversified Trust Co grew its position in AstraZeneca PLC (NASDAQ:AZN) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,630 shares of the company’s stock after purchasing an additional 309 shares during the period. Diversified Trust Co’s holdings in AstraZeneca were worth $369,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of AZN. Stratos Wealth Advisors LLC raised its holdings in AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares in the last quarter. Crumly & Associates Inc. raised its holdings in AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares in the last quarter. Harbour Investments Inc. raised its holdings in AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after acquiring an additional 160 shares in the last quarter. Smith Salley Wealth Management raised its stake in AstraZeneca by 1.0% in the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after buying an additional 162 shares during the period. Finally, Veracity Capital LLC raised its stake in AstraZeneca by 4.5% in the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock valued at $299,000 after buying an additional 164 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Up 0.6 %

Shares of NASDAQ:AZN opened at $67.01 on Friday. The company has a market capitalization of $207.77 billion, a P/E ratio of 32.06, a P/E/G ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business’s 50 day simple moving average is $66.11 and its 200 day simple moving average is $74.89.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. On average, research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.